Clinical Trials at Hackensack University Medical Center

As of June 2026, 135 paid clinical trials are recruiting at Hackensack University Medical Center, located at 30 PROSPECT AVE, HACKENSACK, NJ 07601-1914, phone (201) 996-2210 in Hackensack, New Jersey. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

135 clinical trials at Hackensack University Medical Center

·Clear filters·↓ Download CSV

Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis

for Relapsing Remitting Multiple Sclerosis

3 locations incl. Golden Valley

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT05949580·Recruiting

Apply to this trial

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

for Advanced Solid Tumor

4 locations incl. Hackensack

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06598800·Phase 1·Recruiting

Apply to this trial

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

for Hematopoietic and Lymphatic System Neoplasm

76 locations incl. Mesa

Sponsor: Children's Oncology Group

Sex: All·Age: 15 - 20

Code: NCT06410209·Phase 2·Recruiting

Apply to this trial

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

for Peripheral T-Cell Lymphoma, Not Otherwise Specified

Drug: Soquelitinib

21 locations incl. Duarte

Sponsor: Corvus Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT06561048·Phase 3·Recruiting

Apply to this trial

TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)

for Tricuspid Regurgitation

36 locations incl. Phoenix

Sponsor: P+F Products + Features USA Inc.

Sex: All·Age: 18+

Code: NCT06137807·Recruiting

Apply to this trial

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

for Advanced Melanoma

Drug: Nivolumab

50 locations incl. Gilbert

Sponsor: Replimune, Inc.

Sex: All·Age: 12+

Code: NCT06264180·Phase 3·Recruiting

Apply to this trial

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

for Stage II Nasopharyngeal Carcinoma AJCC v8

Drug: Nivolumab

76 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 21

Code: NCT06064097·Phase 2·Recruiting

Apply to this trial

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

for Lupus Nephritis

19 locations incl. San Francisco

Sponsor: Children's Hospital Medical Center, Cincinnati

Sex: All·Age: 8 - 20

Code: NCT05538208·Phase 2·Recruiting

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

Drug: Ruxolitinib

58 locations incl. Birmingham

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting

Apply to this trial

Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma

for Osteogenic Sarcoma Recurrent

2 locations incl. Hackensack

Sponsor: Hackensack Meridian Health

Sex: All·Age: 8 - 30

Code: NCT05726383·Phase 2·Recruiting

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

156 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting

Apply to this trial

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

7 locations incl. Palo Alto

Sponsor: St. Jude Children's Research Hospital

Sex: All·Age: 8+

Code: NCT06098430·Recruiting

Apply to this trial

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

for Recurrent Langerhans Cell Histiocytosis

104 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 180 Days - 22

Code: NCT05828069·Phase 2·Recruiting

Apply to this trial

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

for Multiple Sclerosis

17 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18 - 60

Code: NCT06220201·Phase 1·Recruiting

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

490 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting

Apply to this trial

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

for Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Drug: Epcoritamab

6 locations incl. Rochester

Sponsor: Academic and Community Cancer Research United

Sex: All·Age: 18+

Code: NCT06238648·Phase 2·Recruiting

Apply to this trial

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

for Refractory Non-Hodgkin Lymphoma

3 locations incl. Duarte

Sponsor: SIRPant Immunotherapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05967416·Phase 1·Recruiting

Apply to this trial

A Global Study of the PETAL Consortium

for T-Cell and NK-Cell Neoplasm

10 locations incl. Duarte

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT06067347·Recruiting

Apply to this trial

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

for Recurrent Glioma

27 locations incl. Aurora

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05859334·Phase 2·Recruiting

Apply to this trial

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

for Solid Tumors

Drug: INCB161734

16 locations incl. Phoenix

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT06179160·Phase 1·Recruiting

Apply to this trial

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

for Hypertension

70 locations incl. Scottsdale

Sponsor: Orchestra BioMed, Inc

Sex: All·Age: 18+

Code: NCT06059638·Recruiting

Apply to this trial

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

for B Acute Lymphoblastic Leukemia Associated With Down Syndrome

69 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 6 - 39

Code: NCT05702645·Recruiting

Apply to this trial

The Fourth Left Atrial Appendage Occlusion Study

for Atrial Fibrillation

51 locations incl. Birmingham

Sponsor: Hamilton Health Sciences Corporation

Sex: All·Age: 18+

Code: NCT05963698·Recruiting

Apply to this trial

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

for Carcinoma, Non-small-Cell Lung

7 locations incl. Newnan

Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Sex: All·Age: 18+

Code: NCT06116786·Phase 1·Recruiting

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1208 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting

Apply to this trial

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

for Mucopolysaccharidosis II

8 locations incl. Oakland

Sponsor: Denali Therapeutics Inc.

Sex: All·Age: Up to 18

Code: NCT06075537·Phase 2, Phase 3·Enrolling By Invitation

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

for Metastatic Breast Cancer

20 locations incl. Gilbert

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT05894239·Phase 3·Recruiting

Apply to this trial

Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

for Heart Failure

47 locations incl. Phoenix

Sponsor: Procyrion

Sex: All·Age: 21+

Code: NCT05677100·Recruiting

Apply to this trial

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

for Cardiovascular Disorder

31 locations incl. Mobile

Sponsor: Children's Oncology Group

Sex: All·Age: 7+

Code: NCT05705531·Recruiting

Apply to this trial

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

for Solid Tumors

11 locations incl. Los Angeles

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT05836324·Phase 1·Recruiting

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

Drug: Venetoclax

44 locations incl. Phoenix

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

820 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Drug: Nivolumab

390 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting

Apply to this trial

XTX301 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

11 locations incl. Sacramento

Sponsor: Xilio Development, Inc.

Sex: All·Age: 18+

Code: NCT05684965·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

for High Grade Osteosarcoma

Drug: Cabozantinib

175 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 40

Code: NCT05691478·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for Multiple Myeloma

13 locations incl. San Francisco

Sponsor: K36 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05651932·Phase 1·Recruiting

Apply to this trial

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

for HER2-positive Breast Cancer

14 locations incl. Los Angeles

Sponsor: Mersana Therapeutics

Sex: All·Age: 18+

Code: NCT05514717·Phase 1·Recruiting

Apply to this trial

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

for Endometrial Carcinoma

403 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05256225·Phase 3·Recruiting

Apply to this trial

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

for Carcinoma, Non-small-Cell Lung

Drug: Amivantamab

26 locations incl. La Jolla

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05498428·Phase 2·Recruiting

Apply to this trial

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

for AML

15 locations incl. Duarte

Sponsor: TScan Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05473910·Phase 1·Recruiting

Apply to this trial